Literature DB >> 8547006

Topical 5-fluorouracil in the treatment of Darier's disease.

A C Knulst1, H B De La Faille, W A Van Vloten.   

Abstract

Two patients suffering from therapy-resistant Darier's disease were treated with topical 5-fluorouracil (5-FU). The drug was applied in a concentration of 1% in a cream base, once daily, in left-right comparison with either 7.5% salicylic acid in petrolatum or 0.05% vitamin A acid cream. Both patients were on long-term treatment with oral retinoids. After 1 week of treatment, a considerable improvement was already apparent on the 5-FU-treated side, in comparison with the salicylic acid- and vitamin A acid-treated sides. Subsequent treatment of all skin lesions with 5-FU for a further 2 weeks resulted in complete clearance of the lesions. Remission periods were of 2-6 months duration. There were no significant adverse effects of treatment. Haematological parameters remained unchanged during the therapy. Topical 5-FU is a safe and useful addition to currently available treatments for Darier's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547006     DOI: 10.1111/j.1365-2133.1995.tb02679.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  [Segmental Darier disease : treatment with pulsed dye laser].

Authors:  L Schmitt; S Roos; C Raulin; S Karsai
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

Review 2.  Management of Darier disease: A review of the literature and update.

Authors:  Roger N Haber; Nicole G Dib
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

3.  Long-term improvement of recalcitrant Darier disease with photon and electron beam radiation therapy.

Authors:  Nicole Leung; Adela R Cardones; Nicole Larrier
Journal:  JAAD Case Rep       Date:  2018-11-14

Review 4.  Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.

Authors:  Nardin Hanna; Megan Lam; Patrick Fleming; Charles W Lynde
Journal:  J Cutan Med Surg       Date:  2021-11-28       Impact factor: 2.854

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.